Depatux-M and temozolomide in advanced high-grade glioma
نویسندگان
چکیده
منابع مشابه
Temozolomide for high grade glioma.
BACKGROUND High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events. OBJECTIVES To assess whether temozolomide has any advantage for treating HGG in either primary or r...
متن کاملBevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
BACKGROUND Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies. We carried out a phase I-II clinical trial with the combination of bevacizumab and continuous dose-intense temozolomide (TMZ) for patients with a r...
متن کاملRapidArc: Initial experience in high grade glioma
Background: Identify the optimal technique of radiotherapy for patients with high grade glioma. Our initial year of experience with RapidArc radiation therapy. Materials and Methods: Planning CT scans of 50 patients with grade IV glioma were reviewed and three plan sets by 3D Conformal Radiotherapy (3DCRT), Intensity Modulated Radiotherapy (IMRT) and Rapid Arc (RA) were generated and the plans ...
متن کاملEfficacy of temozolomide treatment in patients with high-grade glioma.
BACKGROUND Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited. This study assessed the safety and early outcomes of TMZ treatment, with or without combination therapy. PATIENTS AND METHODS The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n...
متن کاملTemozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma
BACKGROUND Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide chemotherapy in patients with low-grade glioma, and assessed progression-free survival outcomes and identified predictive molecular factors. METHODS For ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology Advances
سال: 2020
ISSN: 2632-2498
DOI: 10.1093/noajnl/vdaa063